Gossamer Bio Inc., a clinical biopharmaceutical company, has announced new compensation terms for three non-executive employees. The company's Compensation Committee has approved the grant of non-qualified stock option awards, allowing the purchase of up to 168,750 shares of Gossamer's common stock under their 2023 Employment Inducement Incentive Award Plan. Effective August 5th, 2025, these options are priced at $2.16 per share, matching the closing price on the Nasdaq Global Select Market on that date. The options have a ten-year term and will vest over four years, with an initial 25% vesting after one year and the rest vesting in monthly installments, contingent upon continued employment with the company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gossamer Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250807548306) on August 07, 2025, and is solely responsible for the information contained therein.